These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 29775170)

  • 41. Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.
    Suchkov IA; Martinez-Gonzalez J; Schellong SM; Garbade T; Falciani M;
    Clin Drug Investig; 2018 Feb; 38(2):181-189. PubMed ID: 29214507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Klok FA; Ageno W; Barco S; Binder H; Brenner B; Duerschmied D; Empen K; Faggiano P; Ficker JH; Galiè N; Ghuysen A; Held M; Heydenreich N; Huisman MV; Jiménez D; Kozak M; Lang IM; Lankeit M; Münzel T; Petris A; Pruszczyk P; Quitzau K; Schellong S; Schmidt KH; Stefanovic BS; Verschuren F; Wolf-Puetz A; Meyer G; Konstantinides SV;
    Thromb Haemost; 2017 Dec; 117(12):2425-2434. PubMed ID: 29212130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose heparin plus warfarin administration in non-traumatic dural sinuses thrombosis. A clinical and neuroradiological study.
    Cipri S; Gangemi A; Campolo C; Cafarelli F; Gambardella G
    J Neurosurg Sci; 1998 Mar; 42(1):23-32. PubMed ID: 9766269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
    Field TS; Dizonno V; Almekhlafi MA; Bala F; Alhabli I; Wong H; Norena M; Villaluna MK; King-Azote P; Ratnaweera N; Mancini S; Van Gaal SC; Wilson LK; Graham BR; Sposato LA; Blacquiere D; Dewar BM; Boulos MI; Buck BH; Odier C; Perera KS; Pikula A; Tkach A; Medvedev G; Canfield C; Mortenson WB; Nadeau JO; Alshimemeri S; Benavente OR; Demchuk AM; Dowlatshahi D; Lanthier S; Lee AYY; Mandzia J; Suryanarayan D; Weitz JI; Hill MD;
    Stroke; 2023 Nov; 54(11):2724-2736. PubMed ID: 37675613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct oral anticoagulants in rare venous thrombosis.
    Finazzi G; Ageno W
    Intern Emerg Med; 2016 Mar; 11(2):167-70. PubMed ID: 26875179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
    van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
    PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
    Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct oral anticoagulants for the treatment of cerebral venous thrombosis - a protocol of an international phase IV study.
    van de Munckhof A; Sánchez van Kammen M; Krzywicka K; Aaron S; Aguiar de Sousa D; Antochi F; Arauz A; Barboza MA; Conforto AB; Dentali F; Galdames Contreras D; Ji X; Jood K; Heldner MR; Hernández-Pérez M; Kam W; Kleinig TJ; Kristoffersen ES; Leker RR; Lemmens R; Poli S; Yeşilot N; Wasay M; Wu TY; Arnold M; Lucas-Neto L; Middeldorp S; Putaala J; Tatlisumak T; Ferro JM; Coutinho JM
    Front Neurol; 2023; 14():1251581. PubMed ID: 37780701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicenter, Open-Label, Randomized Controlled Trial of Warfarin and Edoxaban Tosilate Hydrate for the Treatment of Deep Vein Thrombosis in Persons with Severe Motor Intellectual Disabilities.
    Ohmori H; Nakamura M; Kada A; Saito AM; Sanayama Y; Shinagawa T; Fujita H; Wakisaka A; Maruhashi K; Okumura A; Takizawa N; Murata H; Inoue M; Kaneko H; Taniguchi H; Kawasaki M; Sano N; Akaboshi S; Tanuma N; Sone S; Kumode M; Takechi T; Koretsune Y; Sumimoto R; Miyanomae T
    Kurume Med J; 2018 Dec; 65(1):11-16. PubMed ID: 30158356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
    Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.